Do BRD(4)S of a Feather Flock Together?

Dutta, Partha; Gomez, Delphine; Gladwin, Mark T.

doi:10.1161/atvbaha.117.309632

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary arterial hypertension is a clinical pathological entity with manifestations not confined to the lungs [ 33 , 34 , 35 ]. Several studies have reported that many signaling pathways described in PAH also play a crucial role in other diseases in which vascular remodeling occurs, which is also a pathoanatomical characterization of CAD [ 36 , 37 , 38 ]. Evidence has documented that CAD occurs 4 times more frequently in PAH than in the world population, providing a plausible reason to assert a correlation between these two diseases.…”

Section: Resultsmentioning

confidence: 99%

Distinctive Signs of Disease as Deterrents for the Endothelial Function: A Systematic Review

Nappi

Singh

2023

Metabolites

View full text Add to dashboard Cite

Endothelial integrity plays a major role in homeostasis and is responsive to the numerous endogenous factors released. While its functional role in vascular tone is well described, its role in the pathophysiology of cardiovascular disease is of interest as a potential therapeutic target. We performed a systematic review to provide an overview of new therapeutic and diagnostic targets for the treatment of coronary artery disease related to endothelial dysfunction. Databases of PubMed, Ovid’s version of MEDLINE, and EMBASE were interrogated with appropriate search terms. Inclusion criteria have been met by 28 studies that were included in the final systematic review. We identified inflammation, pulmonary hypertension, diabetes mellitus and Fabry disease as pathophysiological mechanisms and explored the therapeutic options related to these conditions including medications such as Canakinumab. Endothelial dysfunction has a key role in several different pathophysiological processes which can be targeted for therapeutic options. Ongoing research should be targeted at making the transition to clinical practice. Further research is also needed on understanding the amelioration of endothelial dysfunction with the use of cardiovascular medications.

show abstract

Section: Resultsmentioning

confidence: 99%

Distinctive Signs of Disease as Deterrents for the Endothelial Function: A Systematic Review

Nappi

Singh

2023

Metabolites

View full text Add to dashboard Cite

show abstract

Stem cell therapy for pulmonary arterial hypertension: An update

Sun

2022

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs

Borck

Guo

Plutzky

2020

Circulation Research

113

View full text Add to dashboard Cite

Epigenetic mechanisms involve the placing (writing) or removal (erasing) of histone modifications that allow heterochromatin to transition to the open, activated euchromatin state necessary for transcription. A third, less studied epigenetic pathway involves the reading of these specific histone marks once placed. The BETs (bromodomain and extraterminal-containing protein family), which includes BRD2, BRD3, and BRD4 and the testis-restricted BRDT, are epigenetic reader proteins that bind to specific acetylated lysine residues on histone tails where they facilitate the assembly of transcription complexes including transcription factors and transcriptional machinery like RNA Polymerase II. As reviewed here, considerable recent data establishes BETs as novel determinants of induced transcriptional programs in vascular cells, like endothelial cells and vascular smooth muscle cells, cardiac myocytes and inflammatory cells, like monocyte/macrophages, cellular settings where these epigenetic reader proteins couple proximal stimuli to chromatin, acting at super-enhancer regulatory regions to direct gene expression. BET inhibition, including the use of specific chemical BET inhibitors like JQ-1, has many reported effects in vivo in the cardiovascular setting, like decreasing atherosclerosis, angiogenesis, intimal hyperplasia, pulmonary arterial hypertension, and cardiac hypertrophy. At the same time, data in endothelial cells, adipocytes, and elsewhere suggest BETs also help regulate gene expression under basal conditions. Studies in the cardiovascular setting have highlighted BET action as a means of controlling gene expression in differentiation, cell identity, and cell state transitions, whether physiological or pathological, adaptive, or maladaptive. While distinct BET inhibitors are being pursued as therapies in oncology, a large prospective clinical cardiovascular outcome study investigating the BET inhibitor RVX-208 (now called apabetalone) has already been completed. Independent of this specific agent and this one trial or the numerous unanswered questions that remain, BETs have emerged as novel epigenetic players involved in the execution of coordinated transcriptional programs in cardiovascular health and disease.

show abstract

Do BRD(4)S of a Feather Flock Together?

Cited by 3 publications

References 20 publications

Distinctive Signs of Disease as Deterrents for the Endothelial Function: A Systematic Review

Distinctive Signs of Disease as Deterrents for the Endothelial Function: A Systematic Review

Stem cell therapy for pulmonary arterial hypertension: An update

BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs

Contact Info

Product

Resources

About